Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fispemifene in Hypogonadal Men with COPD
NCT01061970Phase 2Completed
- Sponsor
- QuatRx Pharmaceuticals
- Start
- Jan 2007
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in Hypogonadism comparing Fispemifene with Placebo (2 arms). Primary endpoint: Change in morning total testosterone levels at 4 weeks. Started Jan 2007; status: completed.
02
Drugs
fispemifene
03
Conditions
Hypogonadism
Beyond the preview
Go deeper on NCT01061970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01061970.